Drug Trial Radar · NCT07118891
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- AbCellera Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or hot flashes, and to postmenopausal women with moderate-to-severe VMS associated with menopause. The safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ABCL635 will be assessed in all study participants; the effects on frequency and severity of VMS will be assessed in postmenopausal women who experience moderate-to-severe symptoms.
Conditions
- Vasomotor Symptoms Associated With Menopause
- Healthy Volunteers
Interventions
ABCL635Biological
Participants will receive SC administrations of ABCL635
PlaceboBiological
Participants will receive SC administration of placebo (5% dextrose solution)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse events (AE)Time frame: Day 0 to day 197
- Number of participants with abnormalities in 12-lead safety electrocardiograms (ECG)Time frame: Day 0 to day 197
- Number of participants with abnormalities in physical examinationTime frame: Day 0 to day 197
- Number of participants with abnormalities in laboratory parameters, including general biochemistry, hematology, endocrinology, and urinalysisTime frame: Day 0 to day 197
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CaRe Clinics
Calgary, Alberta, Canada
CaRe Clinics
Red Deer, Alberta, Canada
Mount Saint Joseph Hospital Clinical Trials Phase 1 Unit
Vancouver, British Columbia, Canada
Centricity Research
Toronto, Ontario, Canada
Centricity Research
Toronto, Ontario, Canada
Alpha Recherche Clinique
Lévis, Quebec, Canada
GCP Research
Montreal, Quebec, Canada
Altasciences Company Inc.
Mount Royal, Quebec, Canada
Clinique RSF Inc.
Québec, Quebec, Canada
Diex Recherche Québec
Québec, Quebec, Canada
Diex Recherche Sherbrooke
Sherbrooke, Quebec, Canada
Diex Recherche Trois-Rivières
Trois-Rivières, Quebec, Canada
Diex Recherche Victoriaville
Victoriaville, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.